Antioxidant targeting by deferiprone in diseases related to oxidative damage

Area of Science:

• Biomedical science
• Pharmacology
• Oxidative stress research

Background:

• Free radical damage (FRD), catalyzed by iron, is implicated in numerous diseases and aging.
• Many antioxidants fail due to insufficient tissue concentrations.
• Existing iron chelators show limited efficacy in reversing FRD-related tissue damage.

Purpose of the Study:

• To evaluate the efficacy of Deferiprone (L1) as an antioxidant pharmaceutical.
• To explore the potential of L1 and other chelators in treating conditions associated with oxidative stress.
• To identify therapeutic strategies for conditions involving iron-catalyzed FRD.

Main Methods:

• Review of existing literature on antioxidant pharmaceuticals and iron chelators.
• Analysis of Deferiprone's (L1) in vitro and in vivo efficacy.
• Structure/activity correlation and ADMET parameter considerations for chelator selection.

Main Results:

• Deferiprone (L1) is the only chelator demonstrated to be effective and safe in reversing oxidative stress-related tissue damage.
• L1 has shown success in iron overload, cardiomyopathy, acute kidney disease, and Friedreich's ataxia.
• L1 effectively reaches both extracellular and intracellular compartments, including the brain.

Conclusions:

• Deferiprone (L1) represents a significant advancement in antioxidant pharmaceutical design.
• L1, other chelators, and their combinations offer potential as primary, adjuvant, or alternative therapies for various diseases.
• Targeted chelator selection based on specific disease parameters is crucial for optimizing therapeutic outcomes.